Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | CRY1 | Q16526 | 16/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 16/20 | 0.34 |
| ▸ | PER2 | O15055 | 14/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921871 | 0.87 | CYP2C9 (0.55) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL3923920 | 0.86 | CYP2C9 (0.37) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL4065119 | 0.84 | CYP2C9 (0.54) | CYP2C9NR1I2CRY1CRY2PLK1 | |
| SCHEMBL3921480 | 0.84 | CYP2C9 (0.55) | CYP2C9NR1I2CRY1CRY2PLK1 | |
| SCHEMBL3921287 | 0.83 | CYP2C9 (0.72) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL4065684 | 0.83 | CYP2C9 (0.54) | CYP2C9NR1I2PLK1 | |
| SCHEMBL4072462 | 0.83 | CYP2C9 (0.52) | CYP2C9NR1I2CRY1CRY2PLK1 | |
| SCHEMBL3930436 | 0.82 | CYP2C9 (0.56) | CYP2C9NR1I2CRY1CRY2PLK1 | |
| SCHEMBL3929718 | 0.81 | CYP2C9 (0.54) | CYP2C9NR1I2CRY1CRY2PER2 | |
| SCHEMBL3924684 | 0.81 | CYP2C9 (0.56) | CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786807-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | claimed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | claimed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | claimed |
| EP-1786807-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| US-20060040927-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040927-A1 | Heterocyclic antiviral compounds | HAVCR2, POLR1A, HCCS | CYP2C9 366/4885NR1I2 239/4885CRY1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.